Find a Clinical Trial

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to moderate symptoms.

Purpose of Study

This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to moderate symptoms. This is a single dose study and three different dose concentrations will be compared to placebo.

Eligibility

Age:
12 +
Sex:
All

Key Inclusion / Exclusion Criteria

Inclusion Criteria:

Otherwise healthy, positive for COVID-19 by an EUA-approved rapid antigen or PCR test, has ongoing “mild to moderate illness or symptoms” with symptom onset starting < 5 days prior to screening visits Must provide written informed consent/assent if a minor which includes signing the institutional review board/independent ethics committee approved consent form prior to participating in any study related activity Willing and able to comply with study procedures and follow-up visits Willing to follow all contraception guidelines Exclusion

Exclusion Criteria:

In the Investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe COVID-19 illness/symptoms Any medical condition that, in the Investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study Has a clinically documents acute infection other than COVID-19 Known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding Has participated, or is participating in a clinical reserach study evaluating COVID-19 convalescent plasma, mAbs against SARS-CoV-2, or IV immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

Conditions:


Notice: Undefined variable: tags_list in /nas/content/live/jshi/wp-content/themes/sorrento/functions.php on line 630

Warning: Invalid argument supplied for foreach() in /nas/content/live/jshi/wp-content/plugins/clinicaltrials/clinicaltrials.php on line 312

Status:

Not yet recruiting

Phase:

Phase 2

Study ID

NCT05372783

Read Detailed Summary

Start Date / End Date:

01/07/2022 -

Enrollment:

700

Full Details:

https://clinicaltrials.gov/ct2/show/NCT05372783

SELECT wp_posts.* FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) INNER JOIN wp_postmeta ON ( wp_posts.ID = wp_postmeta.post_id ) WHERE 1=1 AND ( wp_term_relationships.term_taxonomy_id IN (21) ) AND ( ( wp_postmeta.meta_key = 'study_ctid' AND wp_postmeta.meta_value = 'NCT05372783' ) ) AND ((wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled'))) GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC /* From [sorrentotherapeutics.com/study/study-to-evaluate-the-efficacy-of-in-sti-9199-in-treating-symptomatic-covid-19-in-outpatient-adults-and-adolescents/] in [/nas/content/live/jshi/wp-content/themes/sorrento/single-study.php:255] */